How do we measure adherence to anti-tuberculosis treatment?

References

• World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization; 2015.
   Google Scholar
• World Health Organization. Stop TB Partnership. In: The paradigm shift 2016-2020. Geneva: World Health Organization; 2015.
   Google Scholar
• Babiarz KS, Suen S, Goldhaber-Fiebert JD. Tuberculosis treatment discontinuation and symptom persistence: an observational study of Bihar, India’s public care system covering >100,000,000 inhabitants. BMC Public Health. 2014;14(1):418.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
   Google Scholar
• Jones-López EC, Ayakaka I, Levin J, et al. Effectiveness of the standard WHO recommended retreatment regimen (Category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. Plos Med. 2011;8(3):e1000427.
   Google Scholar
• Lackey B, Seas C, van der Stuyft P, et al. Patient characteristics associated with tuberculosis treatment default: a cohort study in a high-incidence area of Lima, Peru. PLoS One. 2015;10(6):e0128541.
   Google Scholar
• Kayigamba FR, Bakker MI, Mugisha V, et al. Adherence to tuberculosis treatment, sputum smear conversion and mortality: a retrospective cohort study in 48 rwandan clinics. PLoS One. 2013;8:9.
   Web of Science ®Google Scholar
• World Health Organization. Treatment of tuberculosis: guidelines. Geneva: World Health Organization; 2010.
   Google Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 Update. Geneva: World Health Organization; 2011.
   Google Scholar
• Munro S, Lewin S, Smith H, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007 Jul 24;4(7):e238.
   PubMed Web of Science ®Google Scholar
• Haynes R, McDonald H, Garg A, et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2:CD000011.
   Google Scholar
• Toczek A, Cox H, Du Cros P, et al. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(3):299–307.
   PubMed Web of Science ®Google Scholar
• Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ. 1997;315:1403–1406.
   PubMed Web of Science ®Google Scholar
• Garner P, Smith H, Munro S, et al. Promoting adherence to tuberculosis treatment. Bull World Health Organ. 2007;85(5):404–406.
   PubMed Web of Science ®Google Scholar
• Volmink J, Garner P. Interventions for promoting adherence to tuberculosis management. Cochrane.Database.Syst Rev. 2000;4:CD000010.
   Google Scholar
• Weaver MS, Lönnroth K, Howard SC, et al. Interventions to improve adherence to treatment for paediatric tuberculosis in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2015;93(10):700–711B.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Stop TB at the source: WHO report on the tuberculosis epidemic. Geneva: World Health Organization; 1995.
   Google Scholar
• World Health Organization. The five elements of DOTS. Geneva: World Health Organization; 2010.
   Google Scholar
• World Health Organization. Stop TB partnership. Building on and enhancing DOTS to meet the TB-related millennium development goals. Geneva: World Health Organization; 2006.
   Google Scholar
• Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;(11):CD000011.
   Google Scholar
• Liu Q, Abba K, Alejandria MM, et al. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. Cochrane Database Syst Rev. 2014;11:CD006594.
   Google Scholar
• M’imunya JM, Kredo T, Volmink J. Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane Database Syst Rev. 2012;5:CD006591.
   Google Scholar
• Lutge EE, Wiysonge CS, Knight SE, et al. Material incentives and enablers in the management of tuberculosis. Cochrane Database Syst Rev. 2012;1:CD007952.
   Google Scholar
• Fairman K, Matheral B. Evaluating medication adherence: which measure is right for your program?. J Manag Care Pharm. 2000;6(6)499–504.
   Google Scholar
• Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–1090.
   PubMed Web of Science ®Google Scholar
• Namukwaya E, Nakwagala F, Mulekya F, et al. Predictors of treatment failure among pulmonary tuberculosis patients in mulago hospital, Uganda. Afr Health Sci. 2011;11(Suppl 1):S105–S111.
   Google Scholar
• Pettit AC, Cummins J, Kaltenbach LA, et al. Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis. Int J Tuberc Lung Dis. 2013;17(4):486–492.
   PubMed Web of Science ®Google Scholar
• Pinidiyapathirage J, Senaratne W, Wickremasinghe R. Southeast asian J trop med public health prevalence and predictors of default with tuberculosis treatment in Sri Lanka. Chest. 2008;39(6):1076–1082.
   Google Scholar
• Dick J, Lombard C. Shared vision–a health education project designed to enhance adherence to anti-tuberculosis treatment. Int J Tuberc Lung Dis. 1997;1(2):181–186.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Stop TB partnership. In: Suggested language and usage for tuberculosis communications. Geneva: World Health Organization; 2013.
   Google Scholar
• Zachariah R, Harries AD, Srinath S, et al. Language in tuberculosis services: can we change to patient-centred terminology and stop the paradigm of blaming the patients? Int J Tuberc Lung Dis. 2012;16(6):714–717.
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-74–7.
   Web of Science ®Google Scholar
• World Health Organization. Compendium of indicators for monitoring and evaluating national tuberculosis programs. Geneva: World Health Organization; 2004.
   Google Scholar
• World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. Geneva: World Health Organization;  2014.
   Google Scholar
• Herrero MB, Ramos S, Arrossi S. Determinants of non adherence to tuberculosis treatment in Argentina: barriers related to access to treatment. Rev Bras Epidemiol. 2015;18(2):287–298.
   PubMedGoogle Scholar
• Alobu I, Oshi SN, Oshi DC, et al. Risk factors of treatment default and death among tuberculosis patients in a resource-limited setting. Asian Pac J Trop Med. 2014;7(12):977–984.
   PubMed Web of Science ®Google Scholar
• Palanduz A, Gultekin D, Kayaalp N. Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests. Pediatr Pulmonol. 2003;36(1):55–57.
   PubMed Web of Science ®Google Scholar
• Yin X, Tu X, Tong Y, et al. Development and validation of a tuberculosis medication adherence scale. PLoS One. 2012;7(12):e50328.
   Google Scholar
• Das R, Baidya S, Das JC, et al. A study of adherence to DOTS regimen among pulmonary tuberculosis patients in West Tripura District. Indian J Tuberc. 2015;62(2):74–79.
   PubMedGoogle Scholar
• Palme IB, Gudetta B, Bruchfeld J, et al. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J. 2002;21(11):1053–1061.
   PubMed Web of Science ®Google Scholar
• OʼDonnell MR, Wolf A, Werner L, et al. Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. J Acquir Immune Defic Syndr. 2014;67(1):22–29.
   PubMed Web of Science ®Google Scholar
• Mkopi A, Range N, Lwilla F, et al. Validation of indirect tuberculosis treatment adherence measures in a resource-constrained setting. Int J Tuberc Lung Dis. 2014;18(7):804–809.
   PubMed Web of Science ®Google Scholar
• Nackers F, Huerga H, Espié E, et al. Adherence to self-administered tuberculosis treatment in a high HIV-prevalence setting: a cross-sectional survey in Homa Bay, Kenya. PLoS One. 2012;7(3):e32140.
   Google Scholar
• Amuha MG, Kutyabami P, Kitutu FE, et al. Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci. 2009;9(Suppl 1):S8–15.
   PubMed Web of Science ®Google Scholar
• Chirwa T, Nyasulu P, Chirwa E, et al. Levels of tuberculosis treatment adherence among sputum smear positive pulmonary tuberculosis patients attending care at Zomba Central hospital, southern Malawi, 2007-2008. PLoS One. 2013;8(5):e63050.
   Google Scholar
• Nezenega ZS, Gacho YHM, Tafere TE. Patient satisfaction on tuberculosis treatment service and adherence to treatment in public health facilities of Sidama zone, South Ethiopia. BMC Health Serv Res. 2013;13:110.
   PubMed Web of Science ®Google Scholar
• Yao S, Huang W-H, van den Hof S, et al. Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China. BMC Health Serv Res. 2011;11(1):341.
   PubMed Web of Science ®Google Scholar
• Akugizibwe P, Ramakant B. Challenges for community role in tuberculosis response. Lancet. 2010;375(9731):2059–2061.
   PubMed Web of Science ®Google Scholar
• Hou WL, Song FJ, Zhang NX, et al. Implementation and community involvement in DOTS strategy: a systematic review of studies in China [Review article]. Int J Tuberc Lung Dis. 2012;16(11):1433–1440.
   PubMed Web of Science ®Google Scholar
• Garfein RS, Collins K, Muñoz F, et al. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis. 2015;19(9):1057–1064.
   PubMed Web of Science ®Google Scholar
• Hoffman JA, Cunningham JR, Suleh AJ, et al. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. Am J Prev Med. 2010;39(1):78–80.
   PubMed Web of Science ®Google Scholar
• DeMaio J, Schwartz L, Cooley P, et al. The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. Clin Infect Dis. 2001;33(12):2082–2084.
   PubMed Web of Science ®Google Scholar
• Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2007;4:CD003343.
   Google Scholar
• Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;5:CD003343.
   Google Scholar
• Juan G, Lloret T, Perez C, et al. Directly observed treatment for tuberculosis in pharmacies compared with self-administered therapy in Spain. Int J Tuberc Lung Dis. 2006;10(2):215–221.
   PubMed Web of Science ®Google Scholar
• Maruza M, Albuquerque MFPM, Coimbra I, et al. Risk factors for default from tuberculosis treatment in HIV-infected individuals in the state of Pernambuco, Brazil: a prospective cohort study. BMC Infect Dis. 2011;11:351.
   PubMed Web of Science ®Google Scholar
• Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tuberculosis: the importance of direct observation. Bull World Health Organ. 2007;85(5):407–409.
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Goebel K, Brown GV, et al. A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting. Int J Tuberc Lung Dis. 2003;7(9):848–854.
   PubMed Web of Science ®Google Scholar
• Lwilla F, Schellenberg D, Masanja H, et al. Evaluation of efficacy of community-based vs. institutional-based direct observed short-course treatment for the control of tuberculosis in Kilombero district, Tanzania. Trop Med Int Health. 2003;8(3):204–210.
   PubMed Web of Science ®Google Scholar
• Kaplan R, Caldwell J, Hermans S, et al. An integrated community TB-HIV adherence model provides an alternative to DOT for tuberculosis patients in Cape Town. Int J Tuberc Lung Dis. 2016;20(9):1185–1191.
   PubMed Web of Science ®Google Scholar
• Whitfield R, Cope GF. Point-of-care test to monitor adherence to anti-tuberculous treatment. Ann Clin Biochem. 2004;41(Pt 5):411–413.
   PubMed Web of Science ®Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839–854.
   PubMed Web of Science ®Google Scholar
• Zentner I, Schlecht HP, Khensouvann L, et al. Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. BMC Infect Dis. 2016;16:242.
   PubMed Web of Science ®Google Scholar
• Eidus L, Hamilton E. A new method for the determination of n-acetyl isoniazid in urine of ambulatory patients. Am Rev Respir Dis. 1964;89:587–588.
   PubMed Web of Science ®Google Scholar
• Eidus L, Varughese P, Hodgkin MM, et al. Simplification of isoniazid phenotyping procedure to promote its application in the chemotherapy of tuberculosis. Bull World Health Organ. 1973;49(5):507–516.
   PubMed Web of Science ®Google Scholar
• Schraufnagel DE, Stoner R, Whiting E, et al. Testing for isoniazid. An evaluation of the Arkansas method. Chest. 1990;98(2):314–316.
   PubMed Web of Science ®Google Scholar
• Perry S, Hovell MF, Blumberg E, et al. Urine testing to monitor adherence to TB preventive therapy. J Clin Epidemiol. 2002;55(3):235–238.
   PubMed Web of Science ®Google Scholar
• Schmitz KE, Hovell MF, Wong CA, et al. The reliability and practicality of the Arkansas method assay of isoniazid adherence. Clin Nurs Res. 2010;19(2):131–143.
   PubMed Web of Science ®Google Scholar
• Meissner PE, Musoke P, Okwera A, et al. The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda. Int J Tuberc Lung Dis. 2002;6(10):903–908.
   PubMed Web of Science ®Google Scholar
• Guerra RL, Conde MB, Efron A, et al. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med. 2010;104(5):754–757.
   PubMed Web of Science ®Google Scholar
• Nicolau I, Tian L, Menzies D, et al. Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients. PLoS One. 2012;7(9):e45913.
   Google Scholar
• Mkopi A, Range N, Lwilla F, et al. Adherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania. PLoS One. 2012;7(12):e51828.
   Google Scholar
• Soobratty MR, Whitfield R, Subramaniam K, et al. Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis. Eur Respir J. 2014;43(5):1519–1522.
   PubMed Web of Science ®Google Scholar
• Zuur MA, Bolhuis MS, Anthony R, et al. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol. 2016;12(5):509–521.
   PubMed Web of Science ®Google Scholar
• Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167(10):1341–1347.
   PubMed Web of Science ®Google Scholar
• van Tongeren L, Nolan S, Cook VJ, et al. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis. 2013;17(2):221–224.
   PubMed Web of Science ®Google Scholar
• Vu DH, Alffenaar JWC, Edelbroek PM, et al. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des. 2011;17(27):2931–2939.
   PubMed Web of Science ®Google Scholar
• Vu D, Koster R, Bolhuis MS, et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. Talanta. 2014;121:9–17.
   PubMed Web of Science ®Google Scholar
• Hofman S, Bolhuis MS, Koster RA, et al. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis. 2015;7(4):481–495.
   PubMed Web of Science ®Google Scholar
• Mave V, Chandanwale A, Kinikar A, et al. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. Int J Tuberc Lung Dis. 2016;20(6):844–847.
   PubMed Web of Science ®Google Scholar
• Belknap R, Weis S, Brookens A, et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One. 2013;8(1):e53373.
   PubMed Web of Science ®Google Scholar
• Au-Yeung KY, DiCarlo L. Cost comparison of wirelessly vs. directly observed therapy for adherence confirmation in anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2012;16(11):1498–1504.
   PubMed Web of Science ®Google Scholar
• Méda ZC, Lin Y-T, Sombié I, et al. Medication-adherence predictors among patients with tuberculosis or human immunodeficiency virus infection in Burkina Faso. J Microbiol Immunol Infect. 2014;47(3):222–232.
   PubMedGoogle Scholar
• van den Boogaard J, Lyimo RA, Boeree MJ, et al. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89(9):632–639.
   PubMed Web of Science ®Google Scholar
• Kulkarni P, Akarte S, Mankeshwar R, et al. Non-adherence of new pulmonary tuberculosis patients to anti-tuberculosis treatment. Ann Med Health Sci Res. 2013;3(1):67–74.
   PubMedGoogle Scholar
• Zhou C, Chu J, Liu J, et al. Adherence to tuberculosis treatment among migrant pulmonary tuberculosis patients in Shandong, China: a quantitative survey study. PLoS One. 2012;7(12):e52334.
   Google Scholar
• Adane AA, Alene KA, Koye DN, et al. Non-adherence to anti-tuberculosis treatment and determinant factors among patients with tuberculosis in northwest Ethiopia. PLoS One. 2013;8(11):e78791.
   Google Scholar
• Tang Y, Zhao M, Wang Y, et al. Non-adherence to anti-tuberculosis treatment among internal migrants with pulmonary tuberculosis in Shenzhen, China: a cross-sectional study. BMC Public Health. 2015;15:474.
   PubMed Web of Science ®Google Scholar
• Kipp AM, Pungrassami P, Stewart PW, et al. Study of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using validated stigma scales. Int J Tuberc Lung Dis. 2011;15(11):1540–1545.
   PubMed Web of Science ®Google Scholar
• Charokopos N, Tsiros G, Foka A, et al. Modified directly observed treatment for tuberculosis versus self-administered therapy: an observational study in rural Greece. Rural Remote Health. 2114;13(2):2114.
   Google Scholar
• Martins N, Morris P, Kelly PM. Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste. BMJ. 2009;339:b4248.
   Google Scholar
• Maciel ELN, Silva AP, Meireles W, et al. Directly observed therapy using home-based supervisors for treating tuberculosis in Vitória, Brazil. J Bras Pneumol. 2008;34(7):506–513.
   PubMedGoogle Scholar
• Rand CS, Wise RA, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis. 1992;146(6):1559–1564.
   PubMed Web of Science ®Google Scholar
• Gomes VF, Wejse C, Oliveira I, et al. Adherence to isoniazid preventive therapy in children exposed to tuberculosis: a prospective study from Guinea-Bissau. Int J Tuberc Lung Dis. 2011;15(12):1637–1643.
   PubMed Web of Science ®Google Scholar
• Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7–8):1280–1288.
   PubMed Web of Science ®Google Scholar
• Ong’ang’o JR, Mwachari C, Kipruto H, et al. The effects on tuberculosis treatment adherence from utilising community health workers: a comparison of selected rural and urban settings in Kenya. PLoS One. 2014;9(2):e88937.
   Google Scholar
• World Health Organization. mHealth: New horizons for health through mobile technologies. In: Global Observatory for eHealth series. Vol. 3, Geneva: World Health Organization; 2011.
   Google Scholar
• Mahmud N, Rodriguez J, Nesbit J. A text message-based intervention to bridge the healthcare communication gap in the rural developing world. Technol Health Care. 2010;18(2):137–144.
   PubMed Web of Science ®Google Scholar
• Bediang G, Stoll B, Elia N, et al. SMS reminders to improve the tuberculosis cure rate in developing countries (TB-SMS Cameroon): a protocol of a randomised control study. Trials. 2014;15:35.
   PubMed Web of Science ®Google Scholar
• Barclay E. Text messages could hasten tuberculosis drug compliance. Lancet (London, England). 2009;373(9657):15–16.
   PubMed Web of Science ®Google Scholar
• van der Kop ML, Memetovic J, Patel A, et al. The effect of weekly text-message communication on treatment completion among patients with latent tuberculosis infection: study protocol for a randomised controlled trial (WelTel LTBI). BMJ Open. 2014;4(4):e004362.
   Google Scholar
• Khachadourian V, Truzyan N, Harutyunyan A, et al. People-centered tuberculosis care versus standard directly observed therapy: study protocol for a cluster randomized controlled trial. Trials. 2015;16:281.
   PubMed Web of Science ®Google Scholar
• Iribarren S, Beck S, Pearce PF, et al. TextTB: a mixed method pilot study evaluating acceptance, feasibility, and exploring initial efficacy of a text messaging intervention to support TB treatment adherence. Tuberc Res Treat. 2013;2013:349394.
   Google Scholar
• World Healt Organization. Stop TB Partnership. mHealth to Improve TB Care. Geneva: World Health Organization; 2012.
   Google Scholar
• Nglazi MD, Bekker L-G, Wood R, et al. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review protocol. Syst Rev. 2013;2:6.
   PubMedGoogle Scholar
• Fallab-Stubi CL, Zellweger JP, Sauty A, et al. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 1998;2(7):525–530.
   PubMed Web of Science ®Google Scholar
• Trajman A, Long R, Zylberberg D, et al. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14(5):551–559.
   PubMed Web of Science ®Google Scholar
• Hirsch-Moverman Y, Colson PW, Bethel J, et al. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis. 2013;17(9):1178–1185.
   PubMed Web of Science ®Google Scholar
• Broomhead S, Mars M. Retrospective return on investment analysis of an electronic treatment adherence device piloted in the Northern Cape Province. Telemed J E Health. 2012;18(1):24–31.
   PubMed Web of Science ®Google Scholar
• Chen LF, Vander Weg MW, Hofmann DA, et al. The Hawthorne Effect in Infection Prevention and Epidemiology. Infect Control Hosp Epidemiol. 2015;36(12):1444–1450.
   PubMed Web of Science ®Google Scholar
• Ruslami R, van Crevel R, van de Berge E, et al. A step-wise approach to find a valid and feasible method to detect non-adherence to tuberculosis drugs. Southeast Asian J Trop Med Public Health. 2008;39(6):1083–1087.
   PubMedGoogle Scholar